Search Results
Amylyx Pharmaceuticals AMLX Q2 2023 Earnings Call & Presentation
Amylyx Pharmaceuticals' AMX0035 for ALS receives negative CHMP opinion
Community Conversation with Amylyx
2023 WMIF | The Disruptors: The Next Wave of Promising Psychiatry and Neurology Drugs
SAVA Shorts Desperate For Shares..SCPH Confident..BIIB Data..AMLX a Yes | Investing Stocks Springer
HEALEY ALS Platform Trial Weekly Q&A: August 25, 2022 | Massachusetts General Hospital
NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN)
